#1 Clinical Trials Search in Europe

Etavopivat

Etavopivat is an investigational drug being studied in clinical trials for the treatment of blood disorders such as sickle cell disease and thalassemia. These trials aim to evaluate the safety, effectiveness, and pharmacokinetics of etavopivat in various patient populations. The studies explore its potential to improve symptoms, reduce complications, and enhance quality of life for people living with these challenging conditions.

Table of Contents

What is Etavopivat?

Etavopivat, also known as FT-4202, is a new medicine currently being developed to treat various blood disorders[1]. It is a potent, selective, orally bioavailable, small-molecule activator of an enzyme called pyruvate kinase red blood cell (PKR)[1]. In simpler terms, this means that etavopivat is a medication taken by mouth that targets a specific enzyme in red blood cells to improve their function.

What Conditions Does Etavopivat Treat?

Etavopivat is being studied for the treatment of several blood disorders, including:

  • Sickle Cell Disease (SCD): A genetic disorder that affects the shape of red blood cells, causing them to become crescent or “sickle” shaped. This can lead to pain, organ damage, and other complications[2].
  • Thalassemia: An inherited blood disorder that affects the production of hemoglobin, leading to anemia and other health issues[1].
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn’t produce enough healthy blood cells[3].

How Does Etavopivat Work?

Etavopivat works by activating an enzyme called pyruvate kinase in red blood cells. This activation helps improve the function and lifespan of red blood cells. For patients with blood disorders like sickle cell disease or thalassemia, this can lead to several potential benefits:

  • Increased hemoglobin levels: Hemoglobin is the protein in red blood cells that carries oxygen throughout the body. Higher levels can improve oxygen delivery to tissues[1].
  • Reduced need for blood transfusions: Some patients may require fewer blood transfusions, which are often necessary to manage these conditions[1].
  • Decreased complications: By improving red blood cell function, etavopivat may help reduce complications associated with these disorders, such as pain crises in sickle cell disease[4].

Current Clinical Trials

Etavopivat is currently being studied in several clinical trials to evaluate its safety and effectiveness. These trials are investigating the drug’s potential in different patient populations and for various aspects of blood disorders:

  • Safety and effectiveness in adults and adolescents with sickle cell disease or thalassemia[1].
  • Impact on reducing the risk of stroke in children with sickle cell disease[5].
  • Effectiveness in treating anemia in patients with myelodysplastic syndromes[3].
  • Long-term safety and efficacy in patients who have completed previous etavopivat studies[6].

How is Etavopivat Administered?

Etavopivat is taken orally (by mouth) as tablets. In most clinical trials, the typical dose is 400 mg once daily[5]. This is usually given as two 200 mg tablets taken together with a glass of water. Depending on the study, etavopivat may be taken with or without food[7].

Safety and Side Effects

As etavopivat is still in clinical trials, its full safety profile is not yet established. The ongoing studies are closely monitoring for any adverse events (side effects) that may occur. Common methods for assessing safety include:

  • Tracking the number and severity of adverse events[4].
  • Monitoring for any serious side effects[4].
  • Assessing the need for dose interruptions or reductions[3].
  • Evaluating changes in laboratory tests and vital signs[7].

It’s important to note that all medications can have potential side effects, and the full range of possible side effects for etavopivat will become clearer as more research is conducted.

Future Prospects

The development of etavopivat represents a promising new approach to treating blood disorders like sickle cell disease and thalassemia. If proven safe and effective in clinical trials, it could offer several potential benefits:

  • A once-daily oral medication, which may be more convenient than other treatments[4].
  • Potential to reduce the need for blood transfusions in some patients[1].
  • Possible improvements in quality of life, including reduced fatigue and increased exercise tolerance[4].
  • Potential to reduce the risk of complications, such as stroke in children with sickle cell disease[5].

As research continues, more information will become available about the effectiveness and safety of etavopivat. Patients with blood disorders should discuss with their healthcare providers whether participating in a clinical trial or using this medication (if approved) might be appropriate for their individual situation.

Aspect Details
Drug Name Etavopivat (also known as FT-4202)
Administration Oral tablets, typically once daily
Main Conditions Studied Sickle Cell Disease, Thalassemia
Other Conditions Myelodysplastic Syndromes (MDS), Liver Impairment
Key Outcome Measures Vaso-occlusive crises, Hemoglobin levels, Fatigue, Exercise capacity
Safety Assessments Adverse events, Vital signs, Laboratory tests
Study Populations Adults, Adolescents, Children, Healthy volunteers
Study Durations Range from single-dose studies to long-term treatments (up to 264 weeks)

FAQ

  • What is etavopivat? Etavopivat is a new medicine being developed to treat blood disorders like sickle cell disease and thalassemia. It is taken orally (by mouth) and is currently being tested in clinical trials to see how well it works and how safe it is.
  • What conditions is etavopivat being studied for? Etavopivat is primarily being studied for sickle cell disease and thalassemia. Some trials are also looking at its effects in people with liver problems and myelodysplastic syndromes (MDS).
  • How is etavopivat given to patients in clinical trials? In most trials, etavopivat is given as tablets that are taken by mouth once daily. The exact dose may vary depending on the specific study and patient group.
  • What are the main goals of the etavopivat clinical trials? The main goals include assessing the safety of etavopivat, how the body processes the drug (pharmacokinetics), its effectiveness in improving symptoms and reducing complications of blood disorders, and its impact on quality of life measures like fatigue and exercise capacity.
  • Who can participate in etavopivat clinical trials? Participants in etavopivat trials include adults and children with sickle cell disease or thalassemia, healthy volunteers in some studies, and people with specific conditions like liver impairment or MDS in others. Each trial has specific eligibility criteria.

Ongoing Clinical Trials on Etavopivat

  • Study on How Well Etavopivat Works for Adolescents and Adults with Sickle Cell Disease

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium France Greece Italy The Netherlands Spain

  • Long-term safety study of oral etavopivat tablets in children, adolescents and adults with sickle cell disease or thalassaemia who completed previous etavopivat treatment

    Recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy Spain

  • A study to test how etavopivat works and its safety in children with sickle cell disease

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on the Effects of Etavopivat for Patients Aged 12-65 with Sickle Cell Disease

    Not recruiting

    4 1
    Investigated diseases:
    Investigated drugs:
    France Germany Greece Italy Spain

Glossary

  • Pharmacokinetics: The study of how a drug moves through the body, including how it is absorbed, distributed, metabolized, and eliminated.
  • Sickle Cell Disease: An inherited blood disorder where red blood cells become crescent-shaped and can block blood flow, causing pain and organ damage.
  • Thalassemia: An inherited blood disorder that affects the production of hemoglobin, leading to anemia and other health problems.
  • Vaso-occlusive Crisis (VOC): A common and painful complication of sickle cell disease where blood flow is blocked by sickled cells.
  • Hemoglobin: A protein in red blood cells that carries oxygen throughout the body.
  • Anemia: A condition where there are not enough healthy red blood cells to carry adequate oxygen to the body's tissues.
  • Transcranial Doppler (TCD): An ultrasound test used to measure blood flow velocity in the brain's blood vessels, often used to assess stroke risk in sickle cell disease.
  • Myelodysplastic Syndromes (MDS): A group of disorders where the bone marrow doesn't produce enough healthy blood cells.
  • Hepatic Impairment: Reduced liver function, which can affect how drugs are processed in the body.
  • 6-Minute Walk Test (6MWT): A test that measures the distance an individual can walk in 6 minutes to assess exercise capacity and endurance.

References

  1. https://clinicaltrials.gov/study/NCT04987489
  2. https://clinicaltrials.gov/study/NCT05725902
  3. https://clinicaltrials.gov/study/NCT05568225
  4. https://clinicaltrials.gov/study/NCT06612268
  5. https://clinicaltrials.gov/study/NCT05953584
  6. https://clinicaltrials.gov/study/NCT06609226
  7. https://clinicaltrials.gov/study/NCT06581627